• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks
    cannabis investing

    Emerald Health Therapeutics Launches New Product Line

    Bryan Mc Govern
    Jul. 02, 2019 09:01AM PST
    Cannabis Investing News

    Emerald Health Therapeutics announced the introduction of a new health supplement product line, with no cannabis in it, through its joint venture with Emerald Health Naturals.

    Emerald Health Therapeutics (TSXV:EMH,OTCQX:EMHTF) announced the introduction of a new health supplement product line, with no cannabis in it, through its joint venture with Emerald Health Naturals (EHN).

    As quoted in the press release:

    The Endo product line includes Endo Brain, Endo Sleep, Endo Calm, Endo Bliss, Endo Inflame and Endo Omega, and are intended to foster overall health and wellness and potentially enhance the body’s response to conditions such as stress, anxiety, restless sleep, inflammation and pain. These products feature PhytoCann Complex, a proprietary formulation consisting of non-psychoactive, plant-based bioactive compounds that support the body’s endocannabinoid system. All products are manufactured according to strict pharmaceutical quality standards.

    “Apart from our strongly positioned presence in the cannabis space, the Endo product launch allows us to uniquely expand Emerald’s business opportunities by accessing natural health product, pharmacy, and grocery stores, channels unavailable to cannabis products, with our non-cannabis supplements,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “We see non-cannabis endocannabinoid-supporting products as the creation of a distinct and significant new natural health product category. Furthermore, our proprietary active ingredient, Phytocann Complex, offers the potential to be incorporated into an array of supplements, foods, and beverages.”

    Eighty percent of Canadians consume natural health products each year. Emerald aims to widely offer its Endo products in retail outlets and is targeting more than 1,000 natural health product stores, pharmacies and grocery stores in Canada by the end of 2019.

    Click here to read the full press release.

    cannabis investingtsxv:emhcanadaemerald health therapeuticsavtar dhillon
    The Conversation (0)

    Go Deeper

    AI Powered
    Person touching a cannabis plant; Australia map in flag colours.

    ASX Cannabis Stocks: 10 Biggest Companies

    CSE Marijuana Stocks

    CSE Marijuana Stocks

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Cannabis Investing News Stocks

    extractX

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×